Heron Therapeutics | HRTX - Current Liabilities


Heron Therapeutics reported $92.14M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
ALKERMES USD 662.09M 62.59M Jun/2026
Alnylam Pharmaceuticals USD 1.51B 163.04M Jun/2026
Amarin USD 164.2M 15.45M Jun/2026
ANI Pharmaceuticals USD 283.65M 44.14M Jun/2026
Anika Therapeutics USD 22.15M 1.18M Jun/2026
Arrowhead Research USD 283.35M 11.87M Jun/2026
Eisai JPY 393.64B 53.39B Jun/2026
Emergent BioSolutions USD 651.3M 12.7M Dec/2023
GlaxoSmithKline GBP 21.53B 895M Jun/2026
Heron Therapeutics USD 92.14M 1.63M Jun/2026
Insmed USD 438.74M 77.74M Jun/2026
Ligand Pharmaceuticals USD 46.74M 6.07M Jun/2026
Merck USD 27.73B 786M Jun/2026
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Neurocrine Biosciences USD 874.5M 42.8M Jun/2026
Omeros USD 85.5M 2.28M Jun/2025
Pacira USD 122.01M 13.22M Jun/2026
Regeneron Pharmaceuticals USD 5.53B 422.9M Jun/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Ultragenyx Pharmaceutical USD 351M 26M Jun/2026
Veracyte USD 62.74M 6.62M Jun/2026
Vertex Pharmaceuticals USD 3.94B 57.3M Jun/2026